TEPMETKO tepotinib
特泊替尼
Drug Class
MET kinase inhibitorMET 激酶抑制剂
Mechanism
Inhibits MET receptor tyrosine kinase phosphorylation, preventing downstream signaling that drives tumor growth and angiogenesis.通过抑制MET受体酪氨酸激酶的自身磷酸化，阻断导致肿瘤生长和血管生成的下游信号通路的激活。
Approved Indication
Metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations, per its FDA approval.根据美国FDA批准，适用于携带MET外显子14跳跃突变的转移性非小细胞肺癌。
What This Means For Patients
TEPMETKO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.TEPMETKO（特泊替尼）目前未通过中国大陆零售药房渠道销售。优健云可协助安排购买渠道，药品由香港采购发货；如有需要，可协调来华后的临床用药支持。具体供应及患者适用性以医疗预检评估为准。
Regulatory Approvals
- FDA — Approved (2021) — Sources
Pivotal Clinical Evidence
- VISION — Paik et al., N Engl J Med 2020 (NCT02864992) — Sources